Mincheng Yu

机构：Hubei University of Medicine, Mayo Clinic, Fudan University, Advanced Semiconductor Engineering (Taiwan), Zhongshan Hospital, Ministry of Education, National Cheng Kung University · ORCID：0000-0001-9998-5708

发表论文 52 篇 · 总被引 1067 次 · h-index 19

代表论文

• CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma (2024 · Journal of Hepatology · 被引 65)
• ACE2 Enhances Sensitivity to PD-L1 Blockade by Inhibiting Macrophage-Induced Immunosuppression and Angiogenesis (2024 · Cancer Research · 被引 33)
• FMO2 + cancer-associated fibroblasts sensitize anti-PD-1 therapy in patients with hepatocellular carcinoma (2025 · Journal for ImmunoTherapy of Cancer · 被引 22)
• CYP1B1 promotes colorectal cancer liver metastasis by enhancing the growth of metastatic cancer cells via a fatty acids-dependent manner (2023 · Journal of Gastrointestinal Oncology · 被引 13)
• Galectin-4 drives anti-PD-L1/BVZ resistance by regulating metabolic adaptation and tumour-associated neutrophils in hepatocellular carcinoma (2025 · Gut · 被引 10)
• Complement C5 is a novel biomarker for liver metastasis of colorectal cancer (2022 · Journal of Gastrointestinal Oncology · 被引 10)